drugset / Trial / NCT02569489
Dose Escalation Study of HBI-8000 in Combination With Paclitaxel and Trastuzumab in Women With Advanced or Metastatic HER2+ Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
This is a phase I multi-center dose escalation study of the histone deacetylase inhibitor (HDACi) HBI-8000 when given in combination with paclitaxel and trastuzumab in women with advanced or metastatic HER2+ breast cancer.
Timeline
- Start
- 2015-12
- Primary completion
- 2015-12
- Completion
- 2015-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tucidinostat | Small molecule | 15 mg | Oral |
| Subject | Tucidinostat | Small molecule | 20 mg | Oral |
| Subject | Tucidinostat | Small molecule | 25 mg | Oral |
| Background | Paclitaxel | Small molecule | — | Intravenous |
| Background | Trastuzumab | Monoclonal antibody | — | Intravenous |